Inhibitory effect of reserpine on N-2-fluorenylacetamide-induced hepatocarcinogenesis in rats.
The effect of reserpine on N-2-fluorenylacetamide (FAA)-induced hepatocarcinogenesis was examined in female ACI rats. The incidence of hepatocellular altered foci (number/cm2) in rats of group 1 given FAA (0.02% in diet) and reserpine (subcutaneous injections of 1 microgram/g body weight, once a week) simultaneously for 10 weeks, and fed a basal diet for 17 weeks was significantly smaller than that of group 3 exposed to FAA alone for 10 weeks and given the basal diet for the subsequent 17 weeks (1.51 +/- 0.58 vs. 11.46 +/- 3.13, P less than 0.001). Similarly, the incidence of the foci of group 2 given reserpine for 16 weeks after discontinuation of FAA exposure for 10 weeks and a one-week interval of basal diet, was also significantly smaller than that of group 3 (1.51 +/- 0.62 vs. 11.46 +/- 3.13, P less than 0.001). No hepatocellular foci were seen in rats of group 4 given reserpine alone for 27 weeks and group 5 (untreated controls). These results indicate that reserpine has an inhibitory effect on FAA-initiated hepatocarcinogenesis.
D015073:2-Acetylaminofluorene / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000284:Administration, Oral; D000818:Animals; D004347:Drug Interactions; D005260:Female; D007279:Injections, Subcutaneous; D008099:Liver / Q000187:drug effects*; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011912:Rats, Inbred ACI; D012110:Reserpine / Q000494:pharmacology* / Q000627:therapeutic use
D012110:Reserpine; D015073:2-Acetylaminofluorene